{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:52:20Z","timestamp":1788274340450,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81560345"],"award-info":[{"award-number":["81560345"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BAB206050"],"award-info":[{"award-number":["20212BAB206050"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20192ACBL21036"],"award-info":[{"award-number":["20192ACBL21036"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00280-023-04506-x","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T22:11:28Z","timestamp":1675289488000},"page":"203-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials"],"prefix":"10.1007","volume":"91","author":[{"given":"Chenxi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zige","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-0847","authenticated-orcid":false,"given":"Wenxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"issue":"1","key":"4506_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"key":"4506_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-030-20301-6_4","volume":"1152","author":"UM Fahad","year":"2019","unstructured":"Fahad UM (2019) Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 1152:51\u201364","journal-title":"Adv Exp Med Biol"},{"key":"4506_CR3","unstructured":"Budh DP, Sapra A (2022) Breast cancer screening. 2022 17. In: StatPearls. Treasure Island (FL): StatPearls Publishing."},{"key":"4506_CR4","unstructured":"Ben Aziz M, Mukhdomi T (2022) Regional anesthesia for breast reconstruction. 2022 19. In: StatPearls. Treasure Island (FL): StatPearls Publishing."},{"issue":"31","key":"4506_CR5","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997\u20134013","journal-title":"J Clin Oncol"},{"issue":"1","key":"4506_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):61","journal-title":"Breast Cancer Res"},{"issue":"4","key":"4506_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.22836","volume":"110","author":"GJ Morris","year":"2007","unstructured":"Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results database. Cancer 110(4):876\u2013884","journal-title":"Cancer"},{"issue":"15 Pt 1","key":"4506_CR8","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434","journal-title":"Clin Cancer Res"},{"key":"4506_CR9","doi-asserted-by":"crossref","unstructured":"Bergin ART, Loi S (2019) Triple-negative breast cancer: recent treatment advances. F1000Res 8:F1000 Faculty Rev-1342.","DOI":"10.12688\/f1000research.18888.1"},{"issue":"2","key":"4506_CR10","doi-asserted-by":"publisher","first-page":"300060521991019","DOI":"10.1177\/0300060521991019","volume":"49","author":"Z Chen","year":"2021","unstructured":"Chen Z, Wang X, Li X, Zhou Y, Chen K (2021) Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy. J Int Med Res 49(2):300060521991019","journal-title":"J Int Med Res"},{"issue":"4","key":"4506_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/02841860802001467","volume":"47","author":"NH Bjarnason","year":"2008","unstructured":"Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P (2008) Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol 47(4):747\u2013754","journal-title":"Acta Oncol"},{"issue":"1","key":"4506_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.soc.2017.08.004","volume":"27","author":"LN Chaudhary","year":"2018","unstructured":"Chaudhary LN, Wilkinson KH, Kong A (2018) Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? Surg Oncol Clin N Am 27(1):141\u2013153","journal-title":"Surg Oncol Clin N Am"},{"key":"4506_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104806","volume":"156","author":"P JabbarzadehKaboli","year":"2020","unstructured":"JabbarzadehKaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M et al (2020) Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer\u2014a comprehensive review from chemotherapy to immunotherapy. Pharmacol Res 156:104806","journal-title":"Pharmacol Res"},{"issue":"Suppl 1","key":"4506_CR14","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.3747\/co.25.3954","volume":"25","author":"JM Lebert","year":"2018","unstructured":"Lebert JM, Lester R, Powell E, Seal M, McCarthy J (2018) Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 25(Suppl 1):S142\u2013S150","journal-title":"Curr Oncol"},{"issue":"4","key":"4506_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw 18(4):479\u2013489","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"4506_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/13543784.2022.2008354","volume":"31","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD (2022) Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs 31(6):549\u2013555","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"4506_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/13543784.2022.2009456","volume":"31","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Ricci AD, Lanotte L, Lombardi L, Di Federico A, Brandi G et al (2022) Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs 31(6):557\u2013565","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"4506_CR18","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3390\/cancers14092215","volume":"14","author":"R Massafra","year":"2022","unstructured":"Massafra R, Bove S, La Forgia D, Comes MC, Didonna V, Gatta G et al (2022) An invasive disease event-free survival analysis to investigate Ki67 role with respect to breast cancer patients\u2019 age: a retrospective cohort study. Cancers (Basel) 14(9):2215","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4506_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2022.2042252","volume":"31","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G (2022) Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs 31(6):495\u2013498","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"4506_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria TM, Mehta AK, Kothari A, Wang D et al (2019) PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 9(6):722\u2013737","journal-title":"Cancer Discov"},{"issue":"2","key":"4506_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES et al (2021) Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol 32(2):240\u2013249","journal-title":"Ann Oncol"},{"issue":"1","key":"4506_CR22","first-page":"527","volume":"40","author":"M Top\u00e7ul","year":"2018","unstructured":"Top\u00e7ul M, \u00c7eti N\u0130L, \u00d6zba\u015fTuran S, KolusayinOzar M\u00d6 (2018) In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab-paclitaxel on triple-negative and luminal A breast cancer cells. Oncol Rep 40(1):527\u2013535","journal-title":"Oncol Rep"},{"key":"4506_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D'Andrea","year":"2018","unstructured":"D\u2019Andrea AD (2018) Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst) 71:172\u2013176","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"4506_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","volume":"12","author":"A Sonnenblick","year":"2015","unstructured":"Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M (2015) An update on PARP inhibitors\u2013moving to the adjuvant setting. Nat Rev Clin Oncol 12(1):27\u201341","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"4506_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269\u20131282","journal-title":"Lancet Oncol"},{"issue":"4","key":"4506_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19(4):497\u2013509","journal-title":"Lancet Oncol"},{"issue":"1","key":"4506_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1513749","volume":"375","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Olopade OI, DeMichele A, Yau C, Van\u2019t Veer LJ, Buxton MB et al (2016) Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"3","key":"4506_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10637-016-0335-x","volume":"34","author":"S Kummar","year":"2016","unstructured":"Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR et al (2016) Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs 34(3):355\u2013363","journal-title":"Invest New Drugs"},{"issue":"3","key":"4506_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa1011418","volume":"364","author":"J O'Shaughnessy","year":"2011","unstructured":"O\u2019Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205\u2013214","journal-title":"N Engl J Med"},{"issue":"34","key":"4506_CR30","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","volume":"32","author":"J O'Shaughnessy","year":"2014","unstructured":"O\u2019Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M et al (2014) Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32(34):3840\u20133847","journal-title":"J Clin Oncol"},{"issue":"2","key":"4506_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10549-015-3616-8","volume":"154","author":"A Llombart-Cussac","year":"2015","unstructured":"Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balma\u00f1a J et al (2015) SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Res Treat 154(2):351\u2013357","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4506_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"4","key":"4506_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64(4):380\u2013382","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"4506_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753\u2013763","journal-title":"N Engl J Med"},{"issue":"6","key":"4506_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533","journal-title":"N Engl J Med"},{"issue":"5","key":"4506_CR36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P et al (2018) Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 24(5):628\u2013637","journal-title":"Nat Med"},{"issue":"7","key":"4506_CR37","first-page":"1187","volume":"37","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K, Tamura K (2010) Breakthrough breast cancer treatment-PARP inhibitor, BRCA, and triple negative breast cancer. Gan To Kagaku Ryoho 37(7):1187\u20131191","journal-title":"Gan To Kagaku Ryoho"},{"issue":"1","key":"4506_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM et al (2015) Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33(1):13\u201321","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04506-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04506-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T07:04:29Z","timestamp":1679468669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04506-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4506"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04506-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors certify that there is no conflict of interest regarding this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}